SGR 1505
Alternative Names: SGR-1505Latest Information Update: 18 Dec 2023
At a glance
- Originator Schrodinger
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 14 Dec 2023 Adverse events data from a phase I trial in healthy volunteers released by Schrödinger
- 10 Dec 2023 Pharmacodynamics data from a phase I trial in healthy volunteers released by Schrödinger
- 10 Dec 2023 Pharmacodynamics data from preclinical studies in B-cell lymphoma released by Schrödinger